Background
==========

*INSIG2*is considered to be a candidate gene with respect to involvement in the development of obesity. A common variant located 10 kb upstream of the gene, rs7566605, was found to be associated with BMI in a recent genome-wide association study \[[@B1]\]. This association has been suitably replicated in several white \[[@B1]-[@B3]\], African-American \[[@B1]\], and Asian populations \[[@B4]-[@B6]\]. However, the SNP did not have a genetic effect on obesity according to other studies including white \[[@B2],[@B7]-[@B14]\], Afro-Caribbean \[[@B12]\], and Asian populations \[[@B15]-[@B17]\]. Hence, the *INSIG2*polymorphism may have an important effect in overweight populations under certain environmental circumstances, given several positive associations found in studies of overweight subjects \[[@B3],[@B4]\].

INSIG2 has attracted the attention of researchers due to its role in cholesterol metabolism \[[@B18]\]. The protein is known to reside in the endoplasmic reticulum, where it binds to SCAP to inhibit it from convoying SREBPs to the Golgi apparatus \[[@B18]\]. Eventually, INSIG2 prevents SREBP from activating cholesterol synthesis because SREBP cannot be processed and activated by the Golgi enzymes. These actions of INSIG2 were also reported in subsequent research involving mice \[[@B18],[@B19]\]. However, they have not been confirmed in research with human populations \[[@B4],[@B6],[@B8],[@B12],[@B13],[@B15],[@B20]\], although the prevalence of hypercholesterolemia was shown to be reduced in CC homozygotes of rs7566605 in Japanese-American women \[[@B16]\]. Even in that study, the SNP was not found to be associated with the levels of total cholesterol, HDL cholesterol, or triacylglycerol.

In the present study, a replication analysis for the association of rs7566605 with BMI as well as other obesity-related measures was conducted using Korean populations, as controversial results have also been reported with Asian populations. The genetic effects of *INSIG2*rs7566605 on the cholesterol metabolic traits were evaluated in efforts to discover a possible role in human cholesterol metabolism.

Methods
=======

Subjects
--------

The Korean study population consisted of 996 subjects recruited from an obesity clinic at the Kirin Oriental Medical Hospital (Seoul, Korea) and 737 subjects recruited from an obesity clinic at the Yeungnam University Medical Center (Daegu, Korea) \[[@B21],[@B22]\]. The 996 subjects from the Kirin obesity clinic were chosen from 1,302 individuals who came for help for weight control between 2001 and 2004. These subjects did not have chronic diseases, such as hypertension, coronary artery disease, stroke, diabetes, and hyperlipidemia. The 737 healthy unrelated subjects from Daegu, Korea were randomly recruited from an unselected population that came for a routine health check-up at Yeungnam University Hospital. These subjects were not representative of the Korean general population, as they had visited obesity clinics in order to address weight issues and/or as they had been the healthy selected subjects. In order to confirm this association, we recruited 631 subjects from 12 oriental medical hospitals in Korea (this population is hereafter named Multicenter) for 2 years since 2007, in which 266 patients with chronic diseases, like hypertension, hyperlipidemia, diabetes, and stroke were removed from a total of 897 individuals. All subjects provided written informed consent, and this study was approved by the Institutional Review Board of the Korea Institute of Oriental Medicine (for Kirin and Multicenter) and Yeungnam University. With the subjects from the Kirin Oriental Medical Hospital, additional anthropometric features (in this case the fat mass and fat percent) and abdominal fat mass areas were measured. Anthropometric features were measured via bio-impedance analysis using a commercial device (Inbody 2.0 Biospace, Korea). Abdominal fat areas were measured from computerized tomography cross-sectional images (Hispeed CT/e, GE, USA) as previously described \[[@B23],[@B24]\]. Blood samples from all study subjects were drawn in the morning after overnight fasting. They were checked for biochemical measures of glucose, total cholesterol, triglyceride, and HDL cholesterol. They were also used for DNA extraction. The characteristics of the recruited individuals are listed in Table [1](#T1){ref-type="table"}.

###### 

Clinical characteristics of the enrolled subjects from two obesity clinics and Multicenter hospitals

  **Feature**                  **n (female %)**   **All**          **Male**         **Female**
  ---------------------------- ------------------ ---------------- ---------------- ----------------
  **Kirin**                                                                         
  Age (y)                      996(93)            27.9 ± 8.43      29.3 ± 12.1      27.8 ± 8.07
  BMI (Kg/m^2^)                996(93)            26.4 ± 4.70      32.6 ± 5.48      25.9 ± 4.27
  Total cholesterol (mmol/L)   908(93)            4.92 ± 1.59      4.69 ± 1.41      4.93 ± 1.60
  HDL cholesterol (mmol/L)     782(92)            1.60 ± 0.910     1.63 ± 1.29      1.59 ± 0.868
  Triglyceride (mmol/L)        916(93)            1.01 ± 0.602     1.66 ± 1.09      0.963 ± 0.516
  Glucose (mmol/L)             894(93)            5.63 ± 1.69      6.57 ± 2.81      5.57 ± 1.56
  **Yeungnam**                                                                      
  Age (y)                      737(37)            45.5 ± 11.0      43.3 ± 10.6      49.0 ± 10.8
  BMI (Kg/m^2^)                737(37)            27.1 ± 3.44      27.4 ± 30.6      26.5 ± 3.93
  Total cholesterol (mmol/L)   737(37)            5.36 ± 0.960     5.38 ± 0.955     5.32 ± 0.968
  HDL cholesterol (mmol/L)     737(37)            1.37 ± 0.346     1.31 ± 0.329     1.48 ± 0.345
  Triglyceride (mmol/L)        737(37)            1.81 ± 1.39      2.04 ± 1.53      1.41 ± 1.01
  Glucose (mmol/L)             736(37)            5.38 ± 1.36      5.47 ± 1.57      5.21 ± 0.903
  **Multicenter**                                                                   
  Age (y)                      631(64)            43.4 ± 14.0      44.0 ± 13.6      42.1 ± 14.7
  BMI (Kg/m^2^)                627(64)            23.0 ± 3.16      22.7 ± 3.24      23.4 ± 2.99
  Total cholesterol (mmol/L)   600(64)            4.82 ± 0.809     4.84 ± 0.807     4.78 ± 0.815
  HDL cholesterol (mmol/L)     601(64)            0.882 ± 0.0666   0.883 ± 0.0747   0.881 ± 0.0489
  Triglyceride (mmol/L)        600(64)            1.31 ± 0.900     1.13 ± 0.677     1.64 ± 1.13
  Glucose (mmol/L)             600(64)            5.15 ± 0.895     5.10 ± 0.803     5.25 ± 1.04

Mean ± standard deviation values are given.

Genotyping
----------

The rs7566605 SNP of the *INSIG2*gene was genotyped with TaqMan \[[@B25]\], according to the manufacturer\'s instructions (Applied Biosystems, Foster City, CA). The intensities of the fluorescence in the assay products were read with Prism 7900 HT instrument (Applied Biosystems). The genotyping failed in 8 individuals of the Kirin and Yeungnam populations, therefore they were removed in the subsequent analysis (the genotyping call rate was 99.5%.). The genotypes of the rs7566605 SNP in individuals from the Multicenter population were obtained by using the commercial Affymetrix GeneChip^®^Human Mapping 500K Array Set (Affymetrix Inc., CA, USA). The genotyping failed in 6 individuals, and they were also removed in the subsequent analysis (The genotyping call rate was 99.0%.).

Statistical analyses
--------------------

χ^2^tests were used to determine whether the variant was in equilibrium at its locus in the population (Hardy-Weinberg equilibrium). The effects of the genetic polymorphism on obesity-related measures and cholesterol metabolic traits were assessed by an ANOVA for three genotypes or by a T-test for the dominant and recessive models. Meta-analysis was performed to combine statistical information from independent data sets. The results of the meta-analysis are considered more powerful estimates of the true effect size than those of each study. Bonferroni correction for multiple comparisons was also performed to remove any false positives. All statistical analyses were performed using SAS, version 8.02 (SAS, USA) and Matlab, Version 7.6 (MathWorks, Natick, MA).

Results
=======

Association analyses with obesity-related measures
--------------------------------------------------

Replication analyses were performed for the association of SNP rs7566605 (located 10 kb upstream of the *INSIG2*transcription start site) with BMI in three Korean populations (total *n*= 2,634). The allele of rs7566605 was in Hardy-Weinberg equilibrium in all three populations (*P*= 0.415 for Kirin; *P*= 0.911 for Yeungnam; *P*= 0.806 for Multicenter). The each MAF of the SNP in three populations was very similar to the frequency (0.37) for the white population \[[@B1]\] (0.35 for Kirin and Yeungnam populations and 0.33 for Multicenter population; 0.37 for white population).

Association of the rs7566605 genotype with BMI was not found in all three populations (Table [2](#T2){ref-type="table"}). When association analyses were extended to include other phenotypes in relation to the considered body features (in this case the WHR, fat mass, fat percent, total AFA, and subcutaneous and visceral AFA), no associations were found for Koreans (Table [3](#T3){ref-type="table"}). When the population was divided into two subgroups according to gender (male and female), no associations were shown in either subgroup (Table [2](#T2){ref-type="table"} and Table [3](#T3){ref-type="table"}). Associations with obesity-related traits were also not found after the meta-analysis with three populations (data not shown). Therefore, the association between rs7566605 and BMI (as well as other obesity-related measures) was not suitably replicated in Koreans.

###### 

Association analyses of *INSIG2*rs7566605 with BMI

                                **n (mean ± SD)**                                                                
  ------------- -------- ------ ------------------------------------------------------------- ------------------ ------------------
  Kirin         Total    0.35   428(26.5 ± 4.61)                                              432(26.3 ± 4.74)   131(26.1 ± 4.88)
                                *P*~*ANOVA*~= 0.689, *P*~*dom*~= 0.423, *P*~*rec*~= 0.564                        
                Female   0.35   400(26.1 ± 4.41)                                              400(25.7 ± 3.96)   120(25.8 ± 4.82)
                                *P*~*ANOVA*~= 0.311, *P*~*dom*~= 0.137, *P*~*rec*~= 0.864                        
                Male     0.38   28(32.0 ± 3.98)                                               32(34.2 ± 6.36)    11(29.7 ± 4.79)
                                *P*~*ANOVA*~= 0.040, *P*~*dom*~= 0. 405, *P*~*rec*~= 0.0525                      
  Yeungnam      Total    0.35   312(27.0 ± 3.35)                                              329(27.2 ± 3.57)   93(27.0 ± 3.26)
                                *P*~*ANOVA*~= 0.824, *P*~*dom*~= 0.751, *P*~*rec*~= 0.789                        
                Female   0.34   121(26.1 ± 3.80)                                              119(26.8 ± 4.06)   34(26.3 ± 3.92)
                                *P*~*ANOVA*~= 0.378, *P*~*dom*~= 0.218, *P*~*rec*~= 0.837                        
                Male     0.36   191(27.5 ± 2.93)                                              210(27.3 ± 3.26)   59(27.3 ± 2.78)
                                *P*~*ANOVA*~= 0.765, *P*~*dom*~= 0.464, *P*~*rec*~= 0.835                        
  Multicenter   Total    0.33   272(23.1 ± 3.31)                                              287(22.7 ± 2.99)   66(23.5 ± 3.24)
                                *P*~*ANOVA*~= 0.161, *P*~*dom*~= 0.461, *P*~*rec*~= 0.145                        
                Female   0.35   168(22.9 ± 3.41)                                              183(22.3 ± 3.03)   47(23.4 ± 3.29)
                                *P*~*ANOVA*~= 0.066, *P*~*dom*~= 0.234, *P*~*rec*~= 0.127                        
                Male     0.31   104(23.2 ± 3.15)                                              104(23.4 ± 2.81)   19(23.7 ± 3.18)
                                *P*~*ANOVA*~= 0.790, *P*~*dom*~= 0.581, *P*~*rec*~= 0.585                        

The *P*values for BMI in subjects with minor alleles were assessed by an ANOVA for a difference among three genotypes or by a T-test for the dominant and recessive models. The significant threshold was 0.0015 for the Kirin population (11 phenotypes and 3 different models) and 0.0033 for the Yeungnam and Multicenter populations (5 phenotypes and 3 different models).

###### 

Association analysis of *INSIG2*rs7566605 with the body features of the Kirin population

                                     **n (mean ± SD)**                                                                    
  -------- ------------------ ------ -------------------------------------------------------------- --------------------- ---------------------
  Total    WHR                0.35   428(0.888 ± 0.0728)                                            432(0.885 ± 0.0776)   131(0.887 ± 0.0811)
                                     *P*~*ANOVA*~= 0.825, *P*~*dom*~= 0.554, *P*~*rec*~= 0.977                            
           Fat mass           0.35   428(24.4 ± 8.36)                                               432(23.8 ± 8.77)      131(23.8 ± 8.67)
                                     *P*~*ANOVA*~= 0.590, *P*~*dom*~= 0.305, *P*~*rec*~= 0.689                            
           Fat percent        0.35   428(34.3 ± 5.86)                                               432(33.9 ± 6.13)      131(34.2 ± 6.58)
                                     *P*~*ANOVA*~= 0.526, *P*~*dom*~= 0.318, *P*~*rec*~= 0.869                            
           Total AFA          0.35   422(293 ± 123)                                                 430(291 ± 131)        130(280 ± 122)
                                     *P*~*ANOVA*~= 0.618, *P*~*dom*~= 0.571, *P*~*rec*~= 0.344                            
           Visceral AFA       0.35   422(65.7 ± 43.4)                                               430(65.5 ± 47.1)      130(60.2 ± 40.3)
                                     *P*~*ANOVA*~= 0.439, *P*~*dom*~= 0.626, *P*~*rec*~= 0.164                            
           Subcutaneous AFA   0.35   422(228 ± 98.0)                                                430(225 ± 103)        130(220 ± 101)
                                     *P*~*ANOVA*~= 0.758, *P*~*dom*~= 0.569, *P*~*rec*~= 0.519                            
  Female   WHR                0.35   400(0.882 ± 0.0697)                                            400(0.875 ± 0.0664)   120(0.881 ± 0.0798)
                                     *P*~*ANOVA*~= 0.293, *P*~*dom*~= 0.175, *P*~*rec*~= 0.782                            
           Fat mass           0.35   400(23.9 ± 8.17)                                               400(22.9 ± 7.65)      120(23.6 ± 8.64)
                                     *P*~*ANOVA*~= 0.228, *P*~*dom*~= 0.123, *P*~*rec*~= 0.845                            
           Fat percent        0.35   400(34.5 ± 5.89)                                               400(33.9 ± 6.14)      120(34.5 ± 6.62)
                                     *P*~*ANOVA*~= 0.332, *P*~*dom*~= 0.261, *P*~*rec*~= 0.576                            
           Total AFA          0.35   394(285 ± 119)                                                 398(276 ± 118)        119(277 ± 121)
                                     *P*~*ANOVA*~= 0.544, *P*~*dom*~= 0.270, *P*~*rec*~= 0.742                            
           Visceral AFA       0.35   394(607 ± 369)                                                 398(591 ± 37.8)       119(556 ± 32.9)
                                     *P*~*ANOVA*~= 0.399, *P*~*dom*~= 0.313, *P*~*rec*~= 0.192                            
           Subcutaneous AFA   0.35   394(225 ± 97.0)                                                398(217 ± 95.0)       119(221 ± 102)
                                     *P*~*ANOVA*~= 0.533, *P*~*dom*~= 0.295, *P*~*rec*~= 0.982                            
  Male     WHR                0.38   28(0.976 ± 0.0598)                                             32(1.02 ± 0.0891)     11(0.954 ± 0.0656)
                                     *P*~*ANOVA*~= 0.0292, *P*~*dom*~= 0.192, *P*~*rec*~= 0.0923                          
           Fat mass           0.38   28(31.2 ± 8.18)                                                32(35.0 ± 13.4)       11(26.1 ± 9.06)
                                     *P*~*ANOVA*~= 0.0629, *P*~*dom*~= 0.589, *P*~*rec*~= 0.0510                          
           Fat percent        0.38   28(32.4 ± 5.12)                                                32(33.9 ± 6.19)       11(30.9 ± 5.23)
                                     *P*~*ANOVA*~= 0.730, *P*~*dom*~= 0.607, *P*~*rec*~= 0.207                            
           Total AFA          0.38   28(406 ± 128)                                                  32(473 ± 146)         11(323 ± 136)
                                     *P*~*ANOVA*~= 0.00778, *P*~*dom*~= 0.422, *P*~*rec*~= 0.0120                         
           Visceral AFA       0.38   28(135 ± 645)                                                  32(146 ± 726)         11(110 ± 72.0)
                                     *P*~*ANOVA*~= 0.345, *P*~*dom*~= 0.928, *P*~*rec*~= 0.213                            
           Subcutaneous AFA   0.38   28(271 ± 103)                                                  32(327 ± 139)         11(213 ± 94.3)
                                     *P*~*ANOVA*~= 0.0199, *P*~*dom*~= 0.347, *P*~*rec*~= 0.0311                          

The *P*values for the AFA in subjects with minor alleles were assessed by an ANOVA for three genotypes or by a T-test for the dominant and recessive models. The significant threshold was 0.0015 for the Kirin population (11 phenotypes and 3 different models).

Association analyses with cholesterol-related phenotypes and glucose
--------------------------------------------------------------------

An association analysis with the plasma levels of glucose and cholesterol-related phenotypes (i.e., total cholesterol, HDL cholesterol, and triglyceride) was performed. No genetic effects of the SNP were detected with the levels of glucose, HDL cholesterol, and triglyceride. Among the three populations, the rs7566605 C allele only appeared to be associated with an increased level of total cholesterol in a dominant genetic model in the Kirin population (Table [4](#T4){ref-type="table"}). When the association was analyzed for subgroups divided by gender, the genetic effects of the rs7566605 seemed to be maintained in female subjects (Table [4](#T4){ref-type="table"}). When the meta-analysis was performed on the three populations (Kirin, Yeungnam, and Multicenter), the rs7566605 C allele was associated in the female subjects with an increased level of total cholesterol (Figure [1](#F1){ref-type="fig"}). After performing a correction for multiple comparisons with the Bonferroni correction, a significant effect could not be found on the plasma levels of the total cholesterol in female subgroups. However, a marginal association was detected in the total cholesterol levels.

![**The pooled effect sizes with 95% CIs for a total cholesterol level in female subgroup**. When the meta-analysis was performed on the three populations, it was found that the rs7566605 SNP was associated with the total cholesterol level in a dominant model, especially in the female subgroup. After performing a Bonferroni correction, a significant effect could not be found on the plasma levels of the total cholesterol (significant threshold: P \< 0.0033).](1471-2350-10-96-1){#F1}

###### 

Association analysis of *INSIG2*rs7566605 with the levels of cholesterol and triglyceride

                                               **n (mean ± SD)**                                                                    
  ----------------- ------------------- ------ -------------------------------------------------------------- --------------------- --------------------
  **Kirin**                                                                                                                         
  Total             Total cholesterol   0.35   389(4.76 ± 1.42)                                               395(5.12 ± 1.77)      122(4.76 ± 1.36)
                                               *P*~*ANOVA*~= 0.00250, *P*~*dom*~= 0.0134, *P*~*rec*~= 0.155                         
                    HDL cholesterol     0.35   341(1.61 ± 0.907)                                              328(1.64 ± 0.970)     111(1.42 ± 0.701)
                                               *P*~*ANOVA*~= 0.0969, *P*~*dom*~= 0.764, *P*~*rec*~= 0.0352                          
                    Triglyceride        0.35   394(1.03 ± 0.567)                                              398(0.968 ± 0.597)    122(1.09 ± 0.708)
                                               *P*~*ANOVA*~= 0.0415, *P*~*dom*~= 0.117, *P*~*rec*~= 0.186                           
  Female            Total cholesterol   0.35   362(4.78 ± 1.44)                                               367(5.14 ± 1.78)      111(4.74 ± 1.34)
                                               *P*~*ANOVA*~= 0.00410, *P*~*dom*~= 0.0170, *P*~*rec*~= 0.178                         
                    HDL cholesterol     0.35   314(1.64 ± 0.904)                                              300(1.61 ± 0.896)     100(1.41 ± 0.618)
                                               *P*~*ANOVA*~= 0.0647, *P*~*dom*~= 0.265, *P*~*rec*~= 0.0203                          
                    Triglyceride        0.35   368(0.996 ± 0.537)                                             370(0.910 ± 0.455)    111(1.02 ± 0.613)
                                               *P*~*ANOVA*~= 0.0396, *P*~*dom*~= 0.0877, *P*~*rec*~= 0.235                          
  Male              Total cholesterol   0.38   27(4.54 ± 1.10)                                                28(4.89 ± 1.65)       11(4.56 ± 1.47)
                                               *P*~*ANOVA*~= 0.629, *P*~*dom*~= 0.480, *P*~*rec*~= 0.728                            
                    HDL cholesterol     0.39   27(1.30 ± 0.891)                                               28(1.95 ± 1.54)       11(1.62 ± 1.30)
                                               *P*~*ANOVA*~= 0.168, *P*~*dom*~= 0.0804, *P*~*rec*~= 0.984                           
                    Triglyceride        0.38   26(1.57 ± 0.708)                                               28(1.73 ± 1.33)       11(1.67 ± 1.26)
                                               *P*~*ANOVA*~= 0.892, *P*~*dom*~= 0.716, *P*~*rec*~= 0.875                            
  **Yeungnam**                                                                                                                      
  Total             Total cholesterol   0.35   312 (5.35 ± 0.913)                                             329 (5.37 ± 0.986)    93(5.39 ± 1.03)
                                               *P*~*ANOVA*~= 0.930, *P*~*dom*~= 0.751, *P*~*rec*~= 0.760                            
                    HDL cholesterol     0.35   312 (1.36 ± 0.336)                                             329 (1.38 ± 0.360)    93(1.37 ± 0.333)
                                               *P*~*ANOVA*~= 0.771, *P*~*dom*~= 0.509, *P*~*rec*~= 0.954                            
                    Triglyceride        0.35   312 (1.83 ± 1.33)                                              329 (1.81 ± 1.54)     93(1.75 ± 0.996)
                                               *P*~*ANOVA*~= 0.802, *P*~*dom*~= 0.675, *P*~*rec*~= 0.726                            
  Female            Total cholesterol   0.34   121(5.22 ± 0.855)                                              119(5.39 ± 1.04)      34(5.44 ± 1.09)
                                               *P*~*ANOVA*~= 0.296, *P*~*dom*~= 0.124, *P*~*rec*~= 0.445                            
                    HDL cholesterol     0.34   121(1.49 ± 0.343)                                              119(1.47 ± 0.357)     34(1.51 ± 0.323)
                                               *P*~*ANOVA*~= 0.813, *P*~*dom*~= 0.755, *P*~*rec*~= 0.670                            
                    Triglyceride        0.34   121(1.46 ± 1.20)                                               119(1.37 ± 0.883)     34(1.38 ± 0.609)
                                               *P*~*ANOVA*~= 0.784, *P*~*dom*~= 0.610, *P*~*rec*~= 0.781                            
  Male              Total cholesterol   0.36   191 (5.43 ± 0.943)                                             210 (5.35 ± 0.956)    59 (5.36 ± 1.01)
                                               *P*~*ANOVA*~= 0.703, *P*~*dom*~= 0.402, *P*~*rec*~= 0.833                            
                    HDL cholesterol     0.36   191 (1.28 ± 0.307)                                             210 (1.33 ± 0.353)    59 (1.29 ± 0.316)
                                               *P*~*ANOVA*~= 0.275, *P*~*dom*~= 0.173, *P*~*rec*~= 0.716                            
                    Triglyceride        0.36   191 (2.06 ± 1.36)                                              210 (2.06 ± 1.77)     59 (1.96 ± 1.11)
                                               *P*~*ANOVA*~= 0.857, *P*~*dom*~= 0.664, *P*~*rec*~= 0.850                            
  **Multicenter**                                                                                                                   
  Total             Total cholesterol   0.34   258(4.80 ± 0.818)                                              277(4.80 ± 0.804)     63(4.97 ± 0.798)
                                               *P*~*ANOVA*~= 0.273, *P*~*dom*~= 0.660, *P*~*rec*~= 0.107                            
                    HDL cholesterol     0.34   258(0.884 ± 0.818)                                             277(1.15 ± 0.293)     64(1.19 ± 0.325)
                                               *P*~*ANOVA*~= 0.870, *P*~*dom*~= 0.625, *P*~*rec*~= 0.965                            
                    Triglyceride        0.34   258(1.31 ± 0.949)                                              277(1.35 ± 0.904)     63(1.15 ± 0.639)
                                               *P*~*ANOVA*~= 0.288, *P*~*dom*~= 0.988, *P*~*rec*~= 0.133                            
  Female            Total cholesterol   0.35   159(4.81 ± 0.798)                                              179(4.81 ± 0.819)     46(5.03 ± 0.780)
                                               *P*~*ANOVA*~= 0.216, *P*~*dom*~= 0.560, *P*~*rec*~= 0.0801                           
                    HDL cholesterol     0.35   159(0.883 ± 0.0539)                                            179(0.883 ± 0.0972)   47(0.879 ± 0.0161)
                                               *P*~*ANOVA*~= 0.943, *P*~*dom*~= 0.894, *P*~*rec*~= 0.733                            
                    Triglyceride        0.35   159(1.18 ± 0.764)                                              179(1.12 ± 0.646)     46(0.99 ± 0.429)
                                               *P*~*ANOVA*~= 0.244, *P*~*dom*~= 0.214, *P*~*rec*~= 0.144                            
  Male              Total cholesterol   0.31   99(4.79 ± 0.852)                                               98(4.77 ± 0.779)      17(4.81 ± 0.845)
                                               *P*~*ANOVA*~= 0.978, *P*~*dom*~= 0.916, *P*~*rec*~= 0.883                            
                    HDL cholesterol     0.31   99(0.884 ± 0.0559)                                             98(0.876 ± 0.0185)    17(0.892 ± 0.102)
                                               *P*~*ANOVA*~= 0.336, *P*~*dom*~= 0.389, *P*~*rec*~= 0.359                            
                    Triglyceride        0.31   99(1.52 ± 1.16)                                                98(1.77 ± 1.13)       17(1.57 ± 0.895)
                                               *P*~*ANOVA*~= 0.300, *P*~*dom*~= 0.157, *P*~*rec*~= 0.817                            

The *P*values for the levels of cholesterol and triglyceride in subjects with minor alleles were assessed by an ANOVA for a difference among three genotypes or by a T-test for the dominant and recessive models. The significant threshold was 0.0015 for the Kirin population (11 phenotypes and 3 different models) and 0.0033 for the Yeungnam and Multicenter populations (5 phenotypes and 3 different models).

Discussion
==========

*INSIG2*, showing involvement with cholesterol metabolism in studies using the cell line and mice, has been identified as an obesity-susceptible gene in a recent whole-genome association study \[[@B1]\]. However, a number of contrasting reports exist regarding the genetic effect of the gene polymorphism (rs7566605) on obesity. The association with BMI also could not be replicated in the present research with Korean populations. The proposed relationship shown in mice between *INSIG2*and cholesterol metabolism has not been verified in human studies of white \[[@B8],[@B12],[@B13]\], African \[[@B12]\], Chinese \[[@B15]\], Japanese \[[@B4]\], and Uyghur \[[@B6]\] populations. Our results demonstrated that the C allele of *INSIG2*rs7566605 did not significantly affect the cholesterol levels.

However, a possible relationship was found between the *INSIG2*and the plasma level of total cholesterol in females (Table [4](#T4){ref-type="table"}). From a high-density SNP analysis in mice, *Insig2*was identified as a susceptible gene in the control of plasma cholesterol levels \[[@B19]\]. *Insig2*has been strongly associated with cholesterol biosynthetic genes that can be activated by *Srebp-2*through construction of a transcriptional network in the female liver. This implies that the carriage of the rs7566605 C allele might weaken the blocking of SREBP activation, leading to elevated total cholesterol levels. However, a relationship between rs7566605 and the cholesterol level could not be established in the present work because there were no significant associations in the meta-analysis and the mean level of the total cholesterol was higher for heterozygotes than those of the major and minor homozygotes in the Kirin population. Therefore, it is necessary to perform an association analysis with other large populations and/or to do research on the subjects who are restricted to having a cholesterol-rich diet during a definite period in order to elucidate the relationship and conclude whether INSIG2 is related with cholesterol metabolism in humans.

Whether INSIG2 plays a role in obesity development in Korean subjects remains unclear, as a relationship between rs7566605 and BMI was not found. However, an association with obesity has been reported in many studies with white, Asian, and African populations \[[@B1]-[@B6],[@B26]\]. According to the results of Cervino et al. \[[@B19]\], *INSIG2*might be related to an increase in fat mass, as *Insig2*was identified upstream of several obesity-related genes in the transcriptional network. This can be supported by a study with double-knockout mice in relation to both *Insig1*and *Insig2*, where mice given a cholesterol-rich diet gained more weight compared to a control group. From a recent study, a new polymorphism, *INSIG2*-102G/A, in high linkage disequilibrium with rs7566605 (D\' = 0.96 and r^2^= 0.04) was found to be related to an increase in BMI and to adipogenesis through SREBP1 activation. However, no connection was found with triglyceride, cholesterol, or glucose \[[@B20]\]. The -102G/A polymorphism has been proposed as the functional polymorphism of *INSIG2*, as it appears to influence the level of *INSIG2*expression directly though the weaker binding of nuclear factors on the -102A DNA fragment. Therefore, the genetic effects of the *INSIG2*gene on fat mass accumulation can be clarified by further studies with the new putative functional variant, and the effects may be strengthened by the habitual ingestion of cholesterol-rich food.

Conclusion
==========

The present study indicates there is no significant relationship between the *INSIG2*gene and cholesterol levels, although the results indicate that the *INSIG2*gene tended to affect the total cholesterol level that was obtained in this study. From human epidemiological studies conducted to date, the influence of *INSIG2*on body fat accumulation and cholesterol metabolism is unclear. Therefore, it is necessary to determine the roles of *INSIG2*in the creation of body fat and in cholesterol metabolism, and to elucidate the interplay among INSIG1 (another INSIG protein), INSIG2, and the SREBP pathway on the two metabolisms.
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